| Private Placement / Financing Transactions
Protego Biopharma: The company raised $130 million of Series B venture funding in a deal led by Novartis Venture Fund and Forbion on December 1, 2025, putting the company’s pre-money valuation at $86.5 million. Scripps Research, MPM BioImpact, Lightspeed Venture Partners, Vida Ventures (Los Angeles), Omega Funds, Digitalis Ventures, YK Bioventures, Droia Ventures and other undisclosed investors also participated in the round. The company is a developer of small molecule therapeutics designed to reprogram protein folding for systemic amyloid and protein misfolding diseases.
TRIANA Biomedicines: The company raised $120 million of Series B venture funding in a deal led by Bessemer Venture Partners and Ascenta Capital on December 3, 2025, putting the company’s pre-money valuation at $138 million. Pfizer Ventures, Regeneron Ventures, The Invus Group, Finchley Healthcare Ventures, YK Bioventures, Atlas Venture, RA Capital Management, Lightspeed Venture Partners and Surveyor Capital also participated in the round. The company is a developer of molecular glue therapeutics for various disease indications.
Excelsior Sciences: The company raised $70 million of Series A venture funding in a deal led by Deerfield Management, Khosla Ventures and Sofinnova Partners on December 3, 2025, putting the company’s pre-money valuation at $26 million. Eli Lilly, Cornucopian Capital, Illinois Ventures, Massachusetts Institute of Technology, Empire State Development and other undisclosed investors also participated in the round. The company also received $25 million of grant funding from Empire State Development. The company is an operator of a chemistry innovation platform providing machine-ready, automated, AI-driven small-molecule discovery and manufacturing.
Artera: The company raised $65 million of venture funding in a deal led by Lead Edge Capital on December 3, 2025. Summation Health Ventures, Heritage Medical Systems, Jackson Square Ventures, and Health Velocity Capital also participated in the round. The company is a developer of a patient communication platform designed to eliminate phone tags and improve the healthcare experience.
Xeltis: The company raised an estimated EUR 50 million of venture funding through a combination of debt and equity on December 2, 2025. An estimated EUR 12.5 million of venture funding was provided by EQT Life Sciences, Invest-NL and other undisclosed investors. An estimated EUR 37.5 million of debt was provided by European Investment Bank. The company is a developer of medical devices for restorative cardiovascular therapy.
Akura Medical: The company raised $53 million of Series C venture funding in a deal led by Qatar Investment Authority on December 1, 2025, putting the company’s pre-money valuation at $162 million. The company is a developer of medical devices for blood clot removal procedures.
SciNeuro Pharmaceuticals: The company raised $53 million of venture funding in a deal led by ARCH Venture Partners and Lilly Asia Ventures on December 4, 2025. The company is a developer of novel therapeutics for CNS diseases and neurological disorders.
Accession Therapeutics: The company raised GBP 30.5 million of venture funding from undisclosed investors on December 4, 2025. The company is a developer of targeted immuno-oncology therapeutics.
Aminex Therapeutics: The company raised $15 million of venture funding from undisclosed investors on December 4, 2025. The company is an operator of a drug development business advancing novel immunotherapies for cancer treatment.
Aether Bio: The company raised $15 million of Series A venture funding in a deal led by Tribe Capital on December 3, 2025, putting the company’s pre-money valuation at $95 million. Henkel Ventures, Radicle Impact, Shrug Capital, Natural Capital (US), Unless, Resilience Reserve, 4DX Ventures, and other undisclosed investors also participated in the round. The company is a developer of a biocatalyst engineering technology designed to repurpose enzymes for novel compound creation.
Curi Bio: The company raised $10 million of Series B venture funding in a deal led by Dream CIS on December 2, 2025, putting the company’s pre-money valuation at $52 million. The company is a developer of a human stem cell-based platform designed to facilitate the discovery of medicines by integrating human cells, systems, and data.
Portrai: The company raised KRW 14.5 billion of Series B venture funding from Pearl Abyss Capital, CKD Venture Capital, and Kakao Ventures on December 2, 2025. BNH Investment, BonAngels Venture Partners, Envisioning Partners, and Stic Alternative also participated in the round. The company is a developer of AI-enabled spatial transcriptomics platforms for enhanced biopsy analysis.
X9: The company raised $8.5 million of venture funding from undisclosed investors on December 5, 2025. The company is a developer of robotic medical imaging and procedural assistance technology intended for minimally invasive diagnostics and interventions.
SMi Systems: The company is in the process of raising GBP 5 million of venture funding on December 1, 2025, putting the company’s pre-money valuation at GBP 35 million. The company is a developer of single-molecule discovery and diagnostic tools designed for biomedical research and clinical diagnostics.
Prokarium: The company raised GBP 4.8 million of venture funding from Flerie on December 2, 2025. The company is an operator of a biopharmaceutical business intended for developing bacterial immunotherapies for cancer.
OYE Therapeutics: The company raised $5.6 million of venture funding in the form of convertible debt from undisclosed investors on December 5, 2025. The company is an operator of a clinical-stage pharmaceutical development business formulating clinical solutions from existing drugs.
Armonica Technologies: The company raised $4.2 million of venture funding from undisclosed investors on December 5, 2025. The company is a developer of long-read DNA sequencing platforms to sequence complete human genomes rapidly.
Bevimi: The company raised an undisclosed amount of venture funding from Able Partners in December 2025. The company is a developer of health and wellness solutions intended to address neuroinflammation and support cognitive performance.
Biocanic: The company raised an undisclosed amount of venture funding from Labcorp Venture Fund in December 2025. The company is a developer of a health intelligence platform designed to manage data-driven insights for health and wellness coaches.
CytoHub: The company raised an undisclosed amount of venture funding from Red Cedar Ventures in December 2025. The company is a developer of a cell biology research and development platform designed to support discovery and preclinical programs.
Eon Systems: The company raised an undisclosed amount of venture funding from Untapped Ventures and Reified in December 2025. The company is an operator of a neurotechnology business intended to emulate human-scale intelligence through fidelity brain mapping and digital reconstruction.
Tessera Therapeutics: The company is in the process of raising $150 million of venture funding from Regeneron Pharmaceuticals as of December 1, 2025. The company is a developer of gene writing technology for permanent genome alterations and modifications.
|
